To Transplant or Not? Weighing the Risks of Blinatumomab Prior to Hematopoietic Stem Cell Transplant in Acute Lymphoblastic Leukemia

Biol Blood Marrow Transplant. 2020 Sep;26(9):e209-e210. doi: 10.1016/j.bbmt.2020.05.012. Epub 2020 May 21.

Authors

Punita Grover¹, Emily Curran²

Affiliations

¹ Department of Internal Medicine, Section of Hematology/Oncology, University of Cincinnati, Cincinnati, Ohio.
² Department of Internal Medicine, Section of Hematology/Oncology, University of Cincinnati, Cincinnati, Ohio. Electronic address: [email protected].

PMID: 32445796
DOI: 10.1016/j.bbmt.2020.05.012

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Bispecific* / adverse effects
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Salvage Therapy

Substances

Antibodies, Bispecific
blinatumomab